MedCity News September 23, 2021
Biotech startup GenEdit is developing polymer nanoparticle technology to deliver genetic medicines, an approach intended to avoid the limitations of viral vectors. Already partnered with a clinical-stage company, it now has financial support from a big pharma giant that joined a syndicate of investors in a $26 million Series A round.
Adeno-associated virus is a workhorse of genetic medicine, serving as the delivery vehicle for a slew of approved and experimental therapies. But adverse effects are a known risk of AAV; injuries and even patient deaths in clinical trials have sparked several clinical holds in the past year. GenEdit aims to avoid those problems by pursuing a different delivery approach altogether.
The South San Francisco-based startup uses polymer nanoparticles to...
Today's Sponsors
Today's Sponsor